Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METROGEL-VAGINAL vs METROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Treatment of bacterial vaginosis (FDA-approved),Off-label: Trichomoniasis, anaerobic bacterial infections
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Hepatic metabolism via oxidation and glucuronidation; major metabolite: hydroxy-metronidazole (active).
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
<20% bound; primarily to serum albumin (minimal binding)
Less than 20%; albumin.
0.25-0.85 L/kg (widely distributed to tissues, including vaginal mucosa and cerebrospinal fluid)
0.25-0.85 L/kg; extensive tissue distribution including CSF.
Intravaginal: Systemic bioavailability approximately 50-60% relative to oral; vaginal absorption variable (mean ~56% of oral dose)
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min); use with caution.
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
No specific Child-Pugh based adjustments available. Use with caution in severe hepatic impairment due to potential metronidazole accumulation.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Safety and efficacy not established in pediatric patients; data insufficient for weight-based dosing.
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
No specific dose adjustment required. Use standard dosing with consideration of age-related decline in renal function and potential for concurrent medications.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
No FDA boxed warning.
No FDA black box warning.
Carcinogenicity: Avoid unnecessary prolonged use; rodent studies showed tumorigenicity.,Peripheral neuropathy: May occur with high doses or prolonged therapy.,Candidiasis: May overgrow Candida; treat concurrent infections.,Neutropenia: Monitor CBC if retreatment needed.,Alcohol interaction: Disulfiram-like reaction (abdominal cramps, nausea, vomiting) if alcohol consumed within 48 hours.,Hepatic impairment: Use with caution; dose adjustment may be needed.
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
Hypersensitivity to metronidazole or nitroimidazoles,Pregnancy: Contraindicated in first trimester (use only if clearly needed in second/third trimester),Use with alcohol or propylene glycol,Use with disulfiram (within 2 weeks)
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
Avoid alcohol and any products containing alcohol (e.g., certain sauces, vinegars, desserts, mouthwashes) during treatment and for at least 48 hours after last dose to prevent disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions.
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations, but some studies suggest a possible association with cleft lip/palate; use only if clearly needed. In the second and third trimesters, no increased risk of fetal abnormalities has been reported. Avoid use in preterm labor or premature rupture of membranes due to potential systemic absorption.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
Metronidazole is excreted in breast milk; after vaginal administration, systemic absorption is minimal (approximately 2% of oral dose), resulting in low milk concentrations. The M/P ratio is approximately 0.8-1.0 for oral dosing; for vaginal gel, ratio is expected lower. The American Academy of Pediatrics considers single-dose therapy compatible with breastfeeding after timed dosing and discarding milk for 12-24 hours. For chronic use, monitor infant for gastrointestinal disturbances.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
No dose adjustment is required for METROGEL-VAGINAL during pregnancy. Systemic absorption is low (<2%), and pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose modification for vaginal administration. Use standard dosage: one applicatorful (5 g containing 37.5 mg metronidazole) intravaginally once or twice daily for 5 days.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
Metronidazole vaginal gel is first-line for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Use caution in patients with Cockayne syndrome due to risk of severe hepatotoxicity. May cause metallic taste. Do not use during menstruation; treatment is typically 5 days but can be extended to 7-10 days for recurrent BV.
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Use the applicator to insert the gel into the vagina as directed, usually once or twice daily for 5 days.,Do not drink alcohol or use alcohol-containing products (mouthwash, cough syrup) during treatment and for 2 days after stopping.,You may notice a metallic taste in your mouth, which is common and harmless.,Avoid sexual intercourse or use condoms during treatment to prevent irritation and reinfection.,Wash hands before and after use. Do not use tampons, douches, or other vaginal products during therapy.
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METROGEL-VAGINAL vs METROGEL, answered by our medical review team.
METROGEL-VAGINAL is a Antibiotic (Nitroimidazole) that works by Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.. METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METROGEL-VAGINAL and METROGEL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METROGEL-VAGINAL is: One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.. The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METROGEL-VAGINAL and METROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METROGEL-VAGINAL is classified as Category C. Metronidazole vaginal gel (METROGEL-VAGINAL) is classified as FDA Pregnancy Category B. In the first trimester, available data do not show an increased risk of major malformations,. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.